Pfizer (PFE) Construction in Progress (2009 - 2013)
Pfizer (PFE) posted quarterly Construction in Progress of $1.1 billion for Q4 2013, up 15.15% year-over-year from $957.0 million in Q4 2012, and up 15.15% quarter-over-quarter from $957.0 million in Q4 2012.
Pfizer (PFE) Construction in Progress (2009 - 2013) Analysis & Trends
Pfizer (PFE) has reported Construction in Progress for 5 consecutive years, with $1.1 billion the latest figure, recorded in Q4 2013.
- In Q4 2013, Construction in Progress rose 15.15% year-over-year to $1.1 billion; the TTM figure through Dec 2013 stood at $1.1 billion (up 15.15% YoY), while the FY2013 annual figure was $1.1 billion, up 15.15% from the prior year.
- Construction in Progress rose to $1.1 billion in Q4 2013 per PFE's latest filing, from $957.0 million in the prior quarter.
- Across five years, Construction in Progress topped out at $2.0 billion in Q4 2009 and bottomed at $957.0 million in Q4 2012.
- Historically, Construction in Progress has averaged $1.3 billion across 5 years, with a median of $1.1 billion in 2013.
- Annual changes were most pronounced in 2010 — Construction in Progress sank 49.19% — and 2011, when it rose 29.53%.
- Pfizer's Construction in Progress stood at $2.0 billion in 2009, then slumped by 49.19% to $999.0 million in 2010, then gained by 29.53% to $1.3 billion in 2011, then slipped by 26.04% to $957.0 million in 2012, then gained by 15.15% to $1.1 billion in 2013.
- Business Quant data shows PFE's Construction in Progress at $1.1 billion in Q4 2013, $957.0 million in Q4 2012, and $1.3 billion in Q4 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | - |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | - |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | - |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | - |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | - |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 1.10 Bn |
| Dec 31, 2012 | 957.00 Mn |
| Dec 31, 2011 | 1.29 Bn |
| Dec 31, 2010 | 999.00 Mn |
| Dec 31, 2009 | 1.97 Bn |